Venous Thromboembolism (VTE) Market is Thriving Worldwide with Surprising Transition During 2021-2026
Venous thromboembolism (VTE) is the formation of blood clots inside the blood vessel. These clots restrict blood flow through the circulatory system. It is classified into two type’s deep vein thrombosis and pulmonary embolism. Formation of blood clot in a deep vein (generally in the leg) is called deep vein thrombosis. The formed deep vein thrombosis clot break off and travels to the lungs, called as pulmonary embolism. Pulmonary embolism is a serious complication from deep vein thrombosis. It occurs in almost one-third of patients suffering from deep vein thrombosis.
Evidence based guidelines are available to support healthcare providers in clinical decision making of the treatment of pulmonary embolism or deep vein thrombosis that should further boost venous thromboembolism treatment market growth. Furthermore, increasing demand for cost-effective treatment are aspects expected to accelerate business growth. Additionally, growing retrieval rate of inferior vena cava filters fosters venous thromboembolism treatment market growth. However, rising preference for drug based venous thromboembolism treatment might hamper industry growth to some extent.
Major players in the global venous thromboembolism market include Pfizer Inc., Boehringer Ingelheim GmbH, Sanofi S.A., Abbott Laboratories, Dupont Pharm Co, Bristol-Myers Squibb Company, Merck & Co. Inc., Bayer AG, Upsher-Smith Laboratories, Inc., and 3M Health Care.

Comments
Post a Comment